Cargando…

Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018–20)

OBJECTIVES: To determine the in vitro susceptibility of Enterobacterales (n = 5457) and Pseudomonas aeruginosa (n = 1949) isolated from hospitalized patients in Africa (three countries) and the Middle East (five countries) in 2018–20 to a panel of 11 antimicrobials and to identify β-lactamase/carbap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karlowsky, James A, Bouchillon, Samuel K, El Mahdy Kotb, Ramy, Mohamed, Naglaa, Stone, Gregory G, Sahm, Daniel F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204471/ https://www.ncbi.nlm.nih.gov/pubmed/35733913 http://dx.doi.org/10.1093/jacamr/dlac060

Ejemplares similares

In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015–18
por: Karlowsky, James A, et al.
Publicado: (2021)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
por: Karlowsky, James A., et al.
Publicado: (2023)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021
por: Wise, Mark G., et al.
Publicado: (2023)

1571. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America During the ATLAS Global Surveillance Program 2017-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
por: Karlowsky, James A., et al.
Publicado: (2021)

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20
por: Karlowsky, James A, et al.
Publicado: (2023)

1569. In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2015-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

1568. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Pediatric Patients, ATLAS Surveillance Program 2015-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
por: Wise, Mark G., et al.
Publicado: (2023)

588. Ceftolozane/Tazobactam Susceptibility of Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacterales Isolates in a Tertiary Hospital in Korea
por: Kim, Kye-Hyung, et al.
Publicado: (2023)

In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program
por: Karlowsky, James A., et al.
Publicado: (2023)

1268. In Vitro Activity of Ceftazidime-Avibactam and Comparators against KPC-Producing Enterobacterales and Pseudomonas aeruginosa Collected in China as Part of the ATLAS Global Surveillance Program in 2019
por: Wise, Mark G G, et al.
Publicado: (2021)

1719. In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2020
por: Estabrook, Mark, et al.
Publicado: (2022)

Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019
por: Gales, Ana C, et al.
Publicado: (2023)

1580. In Vitro Activity of Ceftazidime-Avibactam Against Enterobacterales and Pseudomonas aeruginosa Collected in Latin America as part of the ATLAS Global Surveillance Program, 2017-2019
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016–2018
por: Paveenkittiporn, Wantana, et al.
Publicado: (2021)

Virulence Factors Of Carbapenem-Resistant Pseudomonas aeruginosa In Hospital-Acquired Infections In Mansoura, Egypt
por: El-Mahdy, Rasha, et al.
Publicado: (2019)

1582. In Vitro Activity of Ceftolozane/Tazobactam against Enterobacterales and Pseudomonas aeruginosa Isolates from Geriatric Patients in the Asia/Pacific region – SMART 2016-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

2826. Epidemiology of Extended Spectrum Beta-lactamase (ESBL)-producing Enterobacterales and Antimicrobial Resistance in Urinary Tract Infection (UTI) and Acute Pyelonephritis (AP)
por: Fernandez, Maria, et al.
Publicado: (2023)

1264. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Pediatric Patients, ATLAS Surveillance Program 2016-2019
por: Kazmierczak, Krystyna, et al.
Publicado: (2021)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21
por: Karlowsky, James A, et al.
Publicado: (2023)

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection
por: Karlowsky, James A., et al.
Publicado: (2022)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019
por: Estabrook, Mark, et al.
Publicado: (2023)

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales
por: Karlowsky, James A., et al.
Publicado: (2022)

Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems
por: Haenni, Marisa, et al.
Publicado: (2017)

Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
por: Terahara, Fumitaka, et al.
Publicado: (2019)

Diversity of Molecular Mechanisms Conferring Carbapenem Resistance to Pseudomonas aeruginosa Isolates from Saudi Arabia
por: Al-Agamy, Mohamed H., et al.
Publicado: (2016)

1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

Carbapenem-resistant Enterobacterales susceptibility patterns to new antimicrobials: A single-center analysis
por: Monk, Miranda, et al.
Publicado: (2023)

Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile
por: Pragasam, Agila K., et al.
Publicado: (2016)

Distinctive Regulation of Carbapenem Susceptibility in Pseudomonas aeruginosa by Hfq
por: Sonnleitner, Elisabeth, et al.
Publicado: (2020)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
por: Shrief, Raghdaa, et al.
Publicado: (2022)

2166. Real-world susceptibilities to newer antibiotics in Enterobacterales and Pseudomonas aeruginosa including carbapenem non-susceptible and multi-drug resistant isolates : A multicenter analysis
por: Riccobene, Todd, et al.
Publicado: (2023)

2149. In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
por: Wise, Mark G, et al.
Publicado: (2023)

1253. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
por: Hackel, Meredith, et al.
Publicado: (2021)

In vitro activity of imipenem ± aminoglycosides against Pseudomonas aeruginosa and Acinetobacter calcoaceticus / baumanii isolated from patients in ICUs in German hospitals (1999–2002)
por: Mueller, EE, et al.
Publicado: (2003)

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
por: García-Fernández, Sergio, et al.
Publicado: (2023)

Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Han, Renru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dki3sf9965dk423q6p6uvtjj64